Masanobu Kawai

Dr. Masanobu Kawai

1. Department of Bone and Mineral Research, Research Institute, Osaka Women’s and Children’s Hospital, Osaka Prefectural Hospital Organization, 840 Murodo-cho, Izumi, Osaka 594-1101, Japan
+1
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
AJAnders Juul
Anders Juul
PBPhilippe Backeljauw
Philippe Backeljauw
MHMichael Højby
Michael Højby
Masanobu KawaiMasanobu Kawai
Masanobu Kawai
RKRasmus Juul Kildemoes
Rasmus Juul Kildemoes
RHReiko Horikawa
Reiko Horikawa
Investigate efficacy, safety, and tolerability of 3 once-weekly somapacitan doses compared with daily growth hormone (GH) administration in short children born small for gestational age (SGA). Randomised, multi-centre, open-label, controlled phase 2 study comprising a 26-week main phase and a 4-year extension (NCT03878446). The study was conducted at 38 sites across 12 countries. 26-week main phase results are presented here. Sixty-two GH treatment-naïve, prepubertal short children born SGA were randomised and exposed; 61 completed the main phase. Three somapacitan doses (0.16 [n = 12], 0.20 [n = 13], 0.24 [n = 12] mg/kg/week) and 2 daily GH doses (0.035 [n = 12], 0.067 [n = 13] mg/kg/day) were administered subcutaneously. After 26 weeks of treatment, the estimated mean annualised height velocity (HV) was 8.9, 11.0, and 11.3 cm/year for somapacitan 0.16, 0.20, and 0.24 mg/kg/week, respectively, compared to 10.3 and 11.9 cm/year for daily GH 0.035 and 0.067 mg/kg/day. Changes from baseline in HV standard deviation score (SDS), height SDS, and insulin-like growth factor I (IGF-I) SDS showed similar dose-dependent responses. Exposure-response modelling indicated the greatest efficacy correlated with the highest somapacitan exposure. Similar safety and tolerability were demonstrated for all weekly somapacitan and daily GH doses. Based on the totality of data on improvements in height-based parameters combined with exposure-response analyses, somapacitan 0.24 mg/kg/week appears most efficacious, providing similar efficacy, safety, and tolerability as daily GH 0.067 mg/kg/day in short children born SGA after 26 weeks of treatment.

1 January 2022 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
Masanobu KawaiMasanobu Kawai
Masanobu Kawai

1 February 2010 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
Masanobu KawaiMasanobu Kawai
Masanobu Kawai
CRClifford J Rosen
Clifford J Rosen


29 July 2022 in Endocrinology
Verified
Journal Article
Closed access
PDF file
SOShinsuke Onuma
Shinsuke Onuma
SKSaori Kinoshita
Saori Kinoshita
SSShigeki Shimba
Shigeki Shimba
KOKeiichi Ozono
Keiichi Ozono
TMToshimi Michigami
Toshimi Michigami
Masanobu KawaiMasanobu Kawai
Masanobu Kawai
The circadian clock network is an evolutionarily conserved system that regulates systemic metabolism, such as glucose homeostasis. Intestinal tissue is a pivotal organ for the regulation of glucose metabolism, mainly via glucose absorption into the circulation; however, the significance of the intestinal circadian clock network for glucose metabolism remains largely unclear. We herein utilized a mouse model in which Bmal1, a core clock gene, was deleted in an intestine-specific manner (Bmal1Int–/– mice) and demonstrated a rhythmic expression of Sglt1 with its peak at zeitgeber time (ZT) 10.7 ± 2.8 in control mice, whereas this was lost in Bmal1Int–/– mice. Mechanistically, chromatin immunoprecipitation analysis revealed rhythmic binding of CLOCK to the E-box elements in the Sglt1 gene in control mice; however, this was absent in Bmal1Int–/– mice. Accordingly, SGLT1 protein levels were decreased during the dark phase in Bmal1Int–/– mice and this was associated with impaired glucose absorption, leading to a decline in hepatic glycogen levels at ZT4, which was restored by ingestion of high-sucrose water. Additionally, when mice were starved from ZT0, greater expression of the lipolysis-related gene Pnpla2 was observed in adipose tissue of Bmal1Int–/– mice, and this was not noted when glycogen storage was restored by high-sucrose water prior to fasting, suggesting that higher Pnpla2 expression in Bmal1Int–/– mice was likely caused by lower glycogen storage. These results indicate that disruption of the intestinal circadian clock system impairs glucose absorption in the intestine and affects systemic glucose homeostasis.

5 March 2020 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
SOShinsuke Onuma
Shinsuke Onuma
TWTamaki Wada
Tamaki Wada
RARyosuke Araki
Ryosuke Araki
KWKazuko Wada
Kazuko Wada
KTKanako Tanase-Nakao
Kanako Tanase-Nakao
Masanobu KawaiMasanobu Kawai
Masanobu Kawai
MIRAGE syndrome is a recently identified disorder characterized by myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy. It is caused by a gain-of-function variant in the SAMD9 gene, but there is limited knowledge regarding the genotype–phenotype correlation. We herein report a Japanese patient with MIRAGE syndrome carrying a novel de novo heterozygous missense variant in the SAMD9 gene (c.4435 G > T; p.Ala1479Ser).